Equities analysts forecast that ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) will post ($0.19) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for ESSA Pharma’s earnings. The lowest EPS estimate is ($0.21) and the highest is ($0.16). ESSA Pharma reported earnings of ($0.06) per share in the same quarter last year, which suggests a negative year over year growth rate of 216.7%. The company is expected to issue its next quarterly earnings results on Thursday, December 17th.
On average, analysts expect that ESSA Pharma will report full-year earnings of ($1.14) per share for the current year, with EPS estimates ranging from ($1.27) to ($1.08). For the next fiscal year, analysts expect that the business will report earnings of ($0.94) per share, with EPS estimates ranging from ($1.20) to ($0.53). Zacks’ EPS calculations are a mean average based on a survey of research firms that follow ESSA Pharma.
A number of analysts recently commented on the stock. Oppenheimer restated a “buy” rating and set a $9.00 price target on shares of ESSA Pharma in a research note on Monday, August 10th. Bloom Burton restated a “buy” rating and set a $9.00 price target on shares of ESSA Pharma in a research report on Sunday, May 24th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of ESSA Pharma in a research note on Friday, May 15th.
EPIX stock traded up $0.14 during trading on Tuesday, reaching $7.26. 119,769 shares of the stock were exchanged, compared to its average volume of 117,009. The firm has a market cap of $218.01 million, a P/E ratio of -8.64 and a beta of 1.70. The firm’s 50 day moving average is $6.79 and its 200 day moving average is $5.30. ESSA Pharma has a twelve month low of $2.57 and a twelve month high of $7.50.
Institutional investors and hedge funds have recently made changes to their positions in the company. Soleus Capital Management L.P. grew its holdings in shares of ESSA Pharma by 27.3% during the 1st quarter. Soleus Capital Management L.P. now owns 2,080,421 shares of the company’s stock valued at $8,322,000 after purchasing an additional 446,052 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of ESSA Pharma in the first quarter worth about $796,000. Opaleye Management Inc. bought a new stake in shares of ESSA Pharma in the 2nd quarter valued at about $1,085,000. Commonwealth Equity Services LLC boosted its holdings in ESSA Pharma by 15.5% during the 2nd quarter. Commonwealth Equity Services LLC now owns 24,270 shares of the company’s stock valued at $150,000 after acquiring an additional 3,250 shares during the period. Finally, Advisor Group Holdings Inc. purchased a new stake in ESSA Pharma during the 1st quarter valued at about $34,000. Hedge funds and other institutional investors own 48.49% of the company’s stock.
About ESSA Pharma
ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
See Also: What is a Special Dividend?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.